AVTE - Aerovate Therapeutics GAAP EPS of -$0.49 misses by $0.03
- Aerovate Therapeutics press release ( NASDAQ: AVTE ): Q2 GAAP EPS of -$0.49 misses by $0.03 .
- Cash, cash equivalents and short-term investments totaled $152.0 million as of June 30, 2022, compared to $167.4 million as of December 31, 2021.
For further details see:
Aerovate Therapeutics GAAP EPS of -$0.49 misses by $0.03